ArticleChemistry & biodiversity2025
Study on the Screening of Anti-Osteoporosis Components in Processed Epimedium-Based on Spectrum-Effect Analysis.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
- Study on the Screening of Anti-Osteoporosis Components in Processed Epimedium-Based on Spectrum-Effect Analysis.Chemistry & biodiversity · 2025Article
- The therapeutic potential of icariin in the intervention of bone and joint diseases through multiple pathways: a narrative review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Epimedium (EP) is a traditional Chinese medicine that has been used to treat osteoporosis for several years, but its mechanism of action is unclear. We used ultrahigh-performance liquid chromatography coupled with triple-quadrupole mass spectrometry (UPLC-QQQ-MS/MS) to detect the components of raw and processed EP samples. The antioxidant activities of the various tested compounds were evaluated using 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH), and their antiosteoporosis effects were assessed in H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.